Metabolically engineered chimeric probiotic-cancer vesicles orchestrate anti-tumor systemic immunity.
The paradigm shift toward patient-centric precision medicine has established personalized cancer vaccines (PCVs) as a key strategy for eliciting tumor-selective immunity. However, traditional cell-based PCVs face significant translational barriers, including manufacturing complexity and safety concerns. While tumor-der...